BRIEF published on 03/20/2025 at 07:05, 1 year ago Innate Pharma annonce une conférence sur les résultats financiers 2024 Résultats Financiers Conférence Téléphonique Cotation Boursière Innate Pharma Immunothérapie Cancer
BRIEF published on 03/20/2025 at 07:05, 1 year ago Innate Pharma Announces 2024 Financial Results Conference Financial Results Conference Call Stock Market Listing Cancer Immunotherapy Innate Pharma
PRESS RELEASE published on 03/20/2025 at 07:00, 1 year ago Informations privilégiées / Autres communiqués Innate Pharma organise une conférence téléphonique et un webcast pour présenter ses résultats financiers 2024. Détails de l'événement et informations pratiques disponibles sur www.innate-pharma.com Résultats Financiers Webcast Conférence Téléphonique Innate Pharma Biotechnologies
PRESS RELEASE published on 03/20/2025 at 07:00, 1 year ago Inside Information / Other news releases Innate Pharma to hold conference call and webcast for full year 2024 financial results on March 27, 2025. Details for participation provided Financial Results Conference Call Biotechnology Webcast Innate Pharma
BRIEF published on 02/17/2025 at 07:07, 1 year 1 month ago Innate Pharma reçoit le statut de "Breakthrough Therapy" de la FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Syndrome De Sézary
BRIEF published on 02/17/2025 at 07:07, 1 year 1 month ago Innate Pharma Receives Breakthrough Therapy Designation from FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Sézary Syndrome
PRESS RELEASE published on 02/17/2025 at 07:02, 1 year 1 month ago Informations privilégiées / Autres communiqués Innate Pharma reçoit le statut de "Breakthrough Therapy" de la FDA pour Lacutamab dans le syndrome de Sézary en rechute ou réfractaire. Accélération du développement réglementaire aux États-Unis FDA Innate Pharma Breakthrough Therapy Lacutamab Syndrome De Sézary
PRESS RELEASE published on 02/17/2025 at 07:02, 1 year 1 month ago Inside Information / Other news releases Innate Pharma receives U.S. FDA Breakthrough Therapy Designation for Lacutamab in Sézary syndrome treatment, showing promising results in Phase 2 TELLOMAK study FDA Innate Pharma Lacutamab Sézary Syndrome Breakthrough Therapy Designation
BRIEF published on 01/27/2025 at 07:05, 1 year 2 months ago Innate Pharma Initiates Phase 1 Study of IPH4502 for Advanced Solid Tumors Phase 1 Trial Innate Pharma IPH4502 Nectin-4 Advanced Solid Tumors
BRIEF published on 01/27/2025 at 07:05, 1 year 2 months ago Innate Pharma lance une étude de phase 1 sur IPH4502 dans les tumeurs solides avancées Innate Pharma Essai De Phase 1 IPH4502 Nectine-4 Tumeurs Solides Avancées
Published on 03/27/2026 at 12:30, 1 hour 30 minutes ago Pasinex Closes First Tranche of Over-Subscribed Non-Brokered Private Placement
Published on 03/27/2026 at 12:00, 2 hours ago Temas Appoints Scientific Advisory Board to Accelerate RCL Commercialisation and Global Development
Published on 03/27/2026 at 11:00, 3 hours ago RE Royalties Announces Strategic Review to Evaluate Path for Long-Term Value Creation
Published on 03/27/2026 at 09:30, 4 hours 30 minutes ago Amap Street Stars Launches Macao Authentic Delicacies Ranking to Drive Cultural-Tourism Innovation in the Greater Bay Area
Published on 03/27/2026 at 13:30, 30 minutes ago Weiqiao Pioneering Group Adds Sixth National 'Green Factory'
Published on 03/27/2026 at 13:30, 30 minutes ago Weiqiao Chuangye : le groupe compte désormais six sites labellisés « usine verte » nationale
Published on 03/27/2026 at 13:00, 1 hour ago NR21: Mise à disposition du Rapport financier annuel 2025
Published on 03/27/2026 at 11:45, 2 hours 15 minutes ago Second National Showcase of Outstanding Works from China’s Rare Operatic Genres Held
Published on 03/27/2026 at 07:00, 7 hours ago WEB SA - CONVOCATION ASSEMBLEE GENERALE ORDINAIRE EXERCICE 2025 - 28/04/2026
Published on 03/26/2026 at 18:17, 19 hours 43 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 19 hours 43 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 20 hours ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
